The British drugmaker’s commitment comes just as some of its pharma peers question their presence in the U.K. amid a widening row there over pricing polices.
Ned Pagliarulo is the Lead Editor at BioPharmaDive. He specializes in medicine and healthcare, with a focus on pharmaceuticals, including topics such as pharmaceutical manufacturing, regulation, gene therapy, and immunology. Ned's insights and expertise have been featured in notable publications including Yahoo Finance, BioPharma Dive, Construction Dive, and Manufacturing Dive.










